Mechanisms of Tissue‐type Plasminogn Activator (tPA) Clearance by the Liver a

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Annals of the New York Academy of Sciences

• Publication date

  1992-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/j.1749-6632.1992.tb51645.xPMID 1339243
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vivo metabolism of human tissue-type plasminogen activator.

  2009cited by this paper
• Characterization of the interaction both in vitro and in vivo of tissue-type plasminogen activator (t-PA) with rat liver cells. Effects of monoclonal antibodies to t-PA.

  1992cited by this paper
• Isolation and characterization of the mannose receptor from human liver potentially involved in the plasma clearance of tissue‐type plasminogen activator

  1992cited by this paper
• Endocytosis of the recombinant tissue plasminogen activator alteplase by hepatic endothelial cells.

  1991cited by this paper
• Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor

  1991cited by this paper
• Binding of tissue-type plasminogen activator by the mannose receptor.

  1991cited by this paper
• Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system.

  1991cited by this paper
• Hepatic Endocytosis of Tissue-Type Plasminogen Activator with Special Reference to the Sinusoidal Cells

  1991cited by this paper
• The receptor for tissue plasminogen activator (t‐PA) in complex with its inhibitor, PAI‐1, on human hepatocytes

  1991cited by this paper
• A mannose receptor is involved in retinal phagocytosis.

  1991cited by this paper
• Isolation and characterization of a mannose receptor from human pigment epithelium.

  1991cited by this paper
• Determinants of Clearance of Tissue-type Plasminogen Activator and their Pharmacologic Implications

  1990cited by this paper
• Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver.

  1990cited by this paper
• Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells.

  1990cited by this paper
• Site-directed mutagenesis in human tissue-plasminogen activator. Distinguishing sites in the amino-terminal region required for full fibrinolytic activity and rapid clearance from the circulation.

  1990cited by this paper
• Tissue plasminogen activator: the biochemistry and pharmacology of variants produced by mutagenesis.

  1990cited by this paper
• Clearance of Tissue Plasminogen Activator by Mannose and Galactose Receptors in the Liver

  1990cited by this paper
• Primary structure of the mannose receptor contains multiple motifs resembling carbohydrate-recognition domains.

  1990cited by this paper
• Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes.

  1990cited by this paper
• Different receptors mediate the hepatic catabolism of tissue-type plasminogen activator and urokinase.

  1990cited by this paper
• Internalization of Recombinant Tissue-Type Plasminogen Activator by Isolated Rat Hepatocytes is via Coated Pits

  1990cited by this paper
• Characterization of 125I-tissue plasminogen activator binding to cerebellar granule neurons

  1989cited by this paper
• Serpin-resistant mutants of human tissue-type plasminogen activator

  1989cited by this paper
• Construction of a tissue plasminogen activator gene having unique restriction sites to facilitate domain manipulation: a model for the analysis of multi-domain proteins.

  1989cited by this paper
• Binding and Degradation of Tissue-Type Plasminogen Activator by the Human Hepatoma Cell Line Hep G2

  1989cited by this paper
• Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

  1989cited by this paper
• Serpin receptor 1: a hepatic receptor that mediates the clearance of antithrombin III-proteinase complexes.

  1989cited by this paper
• Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1.

  1989cited by this paper
• Variants of human tissue-type plasminogen activator substituted at the protease cleavage site and glycosylation sites, and truncated at the N- and C-termini.

  1989cited by this paper
• Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells.

  1989cited by this paper
• Thrombolytic therapy in acute myocardial infarction.

  1989cited by this paper
• Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat.

  1989cited by this paper
• Interactions between tissue-type plasminogen activator and extracellular matrix-associated plasminogen activator inhibitor type 1 in the human hepatoma cell line HepG2.

  1989cited by this paper
• Uptake of human recombinant tissue-type plasminogen activator by rat hepatocytes in vivo: an electron microscope autoradiographic study.

  1989cited by this paper
• Elimination of Native and Carbohydrate-Modified Tissue Plasminogen Activator in Rabbits

  1989cited by this paper
• Pharmacokinetics and isolated liver perfusion of carbohydrate modified recombinant tissue-type plasminogen activator

  1989cited by this paper
• Variants of human tissue‐type plasminogen activator that lack specific structural domains of the heavy chain.

  1988cited by this paper
• Structure-function analysis with tissue-type plasminogen activator. Effect of deletion of NH2-terminal domains on its biochemical and biological properties.

  1988cited by this paper
• Surface Receptors for Urokinase Plasminogen Activator

  1988cited by this paper
• Biodisposition and catabolism of tissue-type plasminogen activator in rats and rabbits

  1988cited by this paper
• Tissue Plasminogen Activator is Endocytosed by Mannose and Galactose Receptors of Rat Liver Cells

  1988cited by this paper
• Functional effects of asparagine-linked oligosaccharide on natural and variant human tissue-type plasminogen activator.

  1988cited by this paper
• The Influence of Carbohydrate Structure on the Clearance of Recombinant Tissue-Type Plasminogen Activator

  1988cited by this paper
• Dose-dependent pharmacokinetics of recombinant tissue-type plasminogen activator in anesthetized dogs following intravenous infusion.

  1988cited by this paper
• Fibrinolysis during liver transplantation in humans: role of tissue-type plasminogen activator.

  1988cited by this paper
• Renal and Hepatic Handling of Endogenous Tissue-Type Plasminogen Activator (t-PA) and Its Inhibitor in Man

  1988cited by this paper
• Mutants of human tissue-type plasminogen activator (t-PA): Structural aspects and functional properties

  1988cited by this paper
• Uptake and Degradation of Tissue Plasminogen Activator in Rat Liver

  1988cited by this paper
• Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator.

  1988cited by this paper
• Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.

  1988cited by this paper
• A tissue-type plasminogen activator mutant with prolonged clearance in vivo. Effect of removal of the growth factor domain.

  1988cited by this paper
• Disposition of a novel recombinant tissue plasminogen activator, delta 2-89 TPA, in mice.

  1988cited by this paper
• Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis.

  1988cited by this paper
• Catabolism of Tissue-Type Plasminogen Activator (t-PA), its Variants, Mutants and Hybrids

  1988cited by this paper
• Characterization of the interaction in vivo of tissue-type plasminogen activator with liver cells.

  1988cited by this paper
• Biochemical determinants of clearance of tissue-type plasminogen activator from the circulation.

  1988cited by this paper
• Disposition of a novel recombinant tissue plasminogen activator, 62–89 tpa, in mice

  1988cited by this paper
• Circulatory metabolism of recombinant tissue-type plasminogen activator in monkeys and rabbits

  1988cited by this paper
• 63 The pharmacokinetics and circulatory metabolism of a long half life mutant of rt-PA

  1988cited by this paper
• Receptor-mediated endocytosis of tissue-type plasminogen activator by the human hepatoma cell line Hep G2.

  1988cited by this paper
• Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers.

  1988cited by this paper
• Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits.

  1988cited by this paper
• Isolation and characterization of a mannose-specific endocytosis receptor from human placenta.

  1987cited by this paper
• Isolation and characterization of a mannose-specific endocytosis receptor from rabbit alveolar macrophages.

  1987cited by this paper
• CELLULAR CATABOLISM OF RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR: IDENTIFICATION AND CHARACTERIZATION OF A NOVEL HIGH AFFINITY UPTAKE SYSTEM ON RAT HEPATOCYTES

  1987cited by this paper
• Epsilon‐aminocaproic Acid for Treatment of Fibrinolysis during Liver Transplantation

  1987cited by this paper
• Isolation and characterization of three different carbohydrate chains from melanoma tissue plasminogen activator.

  1987cited by this paper
• Determinants of clearance of tissue-type plasminogen activator (t-PA) from the circulation

  1987cited by this paper
• A Modified Human Tissue Plasminogen Activator with Extended Half–Life In Vivo

  1987cited by this paper
• The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor.

  1987cited by this paper
• DOSE-DEPENDENT PHARMACOKINETICS OF RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR (tPA) IN ANESTHETIZED DOGS FOLLOWING INTRAVENOUS INFUSION

  1987cited by this paper
• Structure and function of human tissue‐type plasminogen activator (t‐PA)

  1986cited by this paper
• Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis.

  1986cited by this paper
• Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats.

  1986cited by this paper
• Influence of fibrin and liver blood flow on the turnover and the systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator in rabbits.

  1986cited by this paper
• The ligand binding specificity and tissue localization of a rat alveolar macrophage lectin.

  1986cited by this paper
• Pharmacokinetics and Effects on Fibrinolytic and Coagulation Parameters of Two Doses of Recombinant Tissue-Type Plasminogen Activator in Healthy Volunteers

  1986cited by this paper
• Evidence that Leishmania donovani utilizes a mannose receptor on human mononuclear phagocytes to establish intracellular parasitism.

  1986cited by this paper
• Involvement of finger domain and kringle 2 domain of tissue‐type plasminogen activator in fibrin binding and stimulation of activity by fibrin.

  1986cited by this paper
• Autonomous functions of structural domains on human tissue-type plasminogen activator.

  1986cited by this paper
• Hepatic Clearance of Tissue-Type Plasminogen Activator in Rats

  1985cited by this paper
• Catabolism of human tissue plasminogen activator in mice.

  1985cited by this paper
• Dexamethasone increases expression of mannose receptors and decreases extracellular lysosomal enzyme accumulation in macrophages.

  1985cited by this paper
• Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates.

  1985cited by this paper
• Turnover of tissue plasminogen activator in normal and hepatectomized rabbits.

  1985cited by this paper
• Tissue Plasminogen Activator: Chemical and Physiological Aspects

  1984cited by this paper
• Functional properties of carbohydrate-depleted tissue plasminogen activator.

  1984cited by this paper
• Yeast Mannans inhibit binding and phagocytosis of zymosan by mouse peritoneal macrophages

  1983cited by this paper
• Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.

  1982cited by this paper
• Turnover of Human Extrinsic (Tissue-Type) Plasminogen Activator in Rabbits

  1981cited by this paper
• Receptor-mediated pinocytosis of mannose/N-acetylglucosamine-terminated glycoproteins and lysosomal enzymes by macrophages

  1980cited by this paper
• Fibrinolysis and liver regeneration

  1977cited by this paper
• Investigations on the fibrinolytic system in liver cirrhosis.

  1968cited by this paper
• ABNORMAL PLASMINOGEN-PLASMIN SYSTEM ACTIVITY (FIBRINOLYSIS) IN PATIENTS WITH HEPATIC CIRRHOSIS: ITS CAUSE AND CONSEQUENCES.

  1964cited by this paper

• Change in novel plasmin activated clotting time assay predicts hyperfibrinolysis, massive transfusion, and mortality in trauma in under 3 minutes.

  2025cites this paper
• Fibrin and Fibrinolysis in Liver, Kidney, and Lung Transplantation.

  2025cites this paper
• Fibrinolytic Platelet Decoys Reduce Cancer Metastasis by Dissociating Circulating Tumor Cell Clusters

  2024cites this paper
• Commentary on "Robust coagulation activation and coagulopathy in mice with experimental acetaminophen-induced liver failure".

  2023cites this paper
• Fibrinolysis Shutdown and Hypofibrinolysis Are Not Synonymous Terms: The Clinical Significance of Differentiating Low Fibrinolytic States

  2022cites this paper
• Detection of early allograft dysfunction at 30 min of reperfusion in liver transplantation: An intraoperative diagnostic tool with real time assessment of graft function.

  2020cites this paper
• Fibrinolysis Dysregulation Following Trauma

  2020cites this paper
• Liver Failure

  2020cites this paper
• Temporal Changes in Fibrinolysis following Injury

  2020cites this paper
• Involvement of the plasminogen activation system in mammalian reproduction

  2017cites this paper
• Establishment of a fluorescence-based method to evaluate endocytosis of desialylated glycoproteins in vitro.

  2017cites this paper
• The Fibrinolytic Status in Liver Diseases

  2015cites this paper
• [Structure and functions of plasminogen/plasmin system].

  2014cites this paper
• Structure and function of plasminogen/plasmin system

  2014cites this paper
• Influence of resuscitation fluids, fresh frozen plasma and antifibrinolytics on fibrinolysis in a thrombelastography-based, in-vitro, whole-blood model

  2013cites this paper
• Glycosylation of Therapeutic Proteins

  2010cites this paper
• ADIPOCYTE-DERIVED HORMONES AND CARDIOVASCULAR DISEASE

  2010cites this paper
• On the Regulation of the Serine Protease t-PA and its Inhibitor PAI-1 in the Brain

  2010cites this paper
• New insights into the molecular mechanisms of the fibrinolytic system

  2009cites this paper
• Past, present and future of alteplase for acute ischemic stroke

  2008cites this paper
• BLOOD PRESSURE ELEVATION: IMPACT ON CARDIOVASCULAR STRUCTURE AND ENDOGENOUS FIBRINOLYSIS

  2008cites this paper
• Regional fluxes of tissue plasminogen activator in porcine endotoxemia

  2007cites this paper
• Characterization of the Hepatic Disposition of Lanoteplase, a Rationally Designed Variant of Tissue Plasminogen Activator in Rodents

  2007cites this paper
• Formation of fibrin clots in the microcirculation during severe sepsis contributes to organ failure

  2007cites this paper
• in porcine endotoxemia

  2007cites this paper
• Impairment of Endothelial Thromboprotective Function by Haemodynamic and Inflammatory Stress Implications for hypertensive disease

  2007cites this paper
• Alteplase for acute ischemic stroke

  2006cites this paper
• ST-elevation myocardial infarction : studies of outcome in relation to fibrinolysis and ischemia monitoring with on-line vectorcardiography.

  2006cites this paper
• variant of tissue plasminogen activator, in rodents

  2006cites this paper
• Risk markers for a first myocardial infarction

  2005cites this paper
• The fibrinolytic enzyme system : New markers of potential interest in cardiovascular disease

  2005cites this paper
• Coronary release of t-PA

  2002cites this paper
• Studies into endogenous fibrinolysis in the peripheral and coronary vascular beds of man

  2000cites this paper
• Degradation of Tissue-Type Plasminogen Activator by Human Monocyte-Derived Macrophages Is Mediated by the Mannose Receptor and by the Low-Density Lipoprotein Receptor-Related Protein

  2000cites this paper
• Systemic levels and preportal organ release of tissue‐type plasminogen activator are enhanced by PEEP in the pig

  1999cites this paper
• The L-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man.

  1998cites this paper
• An Experimental Multiple-Organ Model for the Study of Regional Net Release/Uptake Rates of Tissue-type Plasminogen Activator in the Intact Pig

  1997cites this paper
• Monoclonal Antibodies against the Human Mannose Receptor that Inhibit the Binding of Tissue-type Plasminogen Activator

  1997cites this paper
• An in vivo Model for the Assessment of Acute Fibrinolytic Capacity of the Endothelium

  1997cites this paper
• Receptor-Mediated Endocytosis

  1996cites this paper
• The human fibrinolytic system.

  1996cites this paper
• Lysine-based Cluster Mannosides That Inhibit Ligand Binding to the Human Mannose Receptor at Nanomolar Concentration*

  1996cites this paper
• Urokinase binding and catabolism by Hep G2 cells is plasminogen activator inhibitor-1 dependent, analogous to interactions of tissue-type plasminogen activator with these cells.

  1995cites this paper
• Receptors for plasminogen and t-PA: an update.

  1995cites this paper
• Plasminogen activators and plasminogen activator inhibitors: biochemical aspects.

  1995cites this paper
• Physiology and pathophysiology of the fibrinolytic system

  1995cites this paper
• Receptor‐mediated endocytosis of plasminogen activators and activator/inhibitor complexes

  1994cites this paper
• In Vitro Stability of a Tissue-Type Plasminogen Activator Mutant, BM 06.022, in Human Plasma

  1994cites this paper
• The Multiligand α2‐Macroglobulin Receptor/Low Density Lipoprotein Receptor‐Related Protein (α2MR/LRP)

  1994cites this paper
• The multiligand alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha 2MR/LRP). Binding and endocytosis of fluid phase and membrane-associated ligands.

  1994cites this paper
• Constitutive synthesis of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAT-1): Conditions and therapeutic targets

  1994cites this paper
• Probing structure-function relationships of tissue-type plasminogen activator by site-specific mutagenesis

  1994cites this paper
• Competition between plasminogen and tissue plasminogen activator for cellular binding sites.

  1993cites this paper
• Studies on the Mechanisms of Action of Steroids on Coagulation and Fibrinolysis

  1992cites this paper